For the best user experience please use a browser to proceed.

EXAS - Exact Sciences Corporation price and analysis

Fundamentals:
Basic Info:
  • Market Cap: 20.20B
  • Exchange: NASDAQ
  • Shares Float: 169,983,000
  • Shares Outstanding: 171,551,000
  • Revenue Per Employee:
Advanced Info:
  • ROE ttm: -24.10 %
  • ROA ttm: -7.61 %
  • Beta: 1.383
  • EPS: -1.763
  • Debt Ratio ttm: 0.46
  • Debt / Equity Ratio ttm: 0.85
  • Payout Ratio ttm:
Cash Ratios:
  • Cash Ratio ttm: 1.76
  • Current Ratio ttm: 2.82
  • Quick Ratio ttm: 2.6
Key Ratios:
  • P/E trailing 12 month: -26.1
  • P/E forward:
  • P/E trailing 12m high: -15.68
  • P/E trailing 12m low: -35.02
  • P/S trailing 12 month: 13.07
  • EV/S trailing 12 month: 13.69
  • P/B trailing 12 month: 5.53
  • PEG ratio: -1.07
Shorts:
  • Shares Short: 9,326,800
  • Shares Short Prev Month: 9,347,300
  • Days to Cover: 7.02
  • Short Percent Float: 5.49 %
  • Short Percent Outstanding: 5.00 %
Ownership:
  • Percent Insiders: 0.75 %
  • Percent Institutions: 93.62 %
Margins:
  • Gross Profit Margin ttm: 76.00 %
  • EBITDA Margin ttm: -11.00 %
  • Operating Margin ttm: -44.10 %
  • Net Income Margin ttm: -50.00 %
Target Prices:
  • Target Price High: 170 USD
  • Target Price Low: 120 USD
  • Target Price Mean: 154.67 USD
  • Number of Analysts: 18
Key Prices:
  • 52 Week High: 158
  • 52 Week Low: 70.75
  • 50 Day Moving Average: 120.56
  • 200 Day Moving Average: 126.73
Dividends:
  • Trailing Dividend yld:
  • Forward Dividend yld:
  • Payout Ratio:
  • Ex-Dividend date: None
Current Quarter Estimates:
  • Current Quarter EPS estimate: -0.98 ~ -0.51 (2021-06-30)
  • Current Quarter revenue estimate: 407.36M ~ 425.80M
  • Median revenue growth YoY estimate: 54.94%
As of: 2021-07-25
Latest News:
5 Best-Performing ETFs of Last WeekNasdaq2021-07-19 14:05:00 EDT
Bull of the Day: Exact Sciences (EXAS)Yahoo Finance2021-07-19 09:20:09 EDT
Where Will ARK Genomic Revolution ETF Be in 5 Years?The Motley Fool2021-07-10 06:12:00 EDT
Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Reb...Zacks Investment Research2021-06-03 12:47:58 EDT
Here's Why You Should Hold on to Exact Sciences (EXAS) StockZacks Investment Research2021-05-26 10:31:07 EDT
Exact Sciences (EXAS) Reveals Promising Data on CologuardZacks Investment Research2021-05-26 08:16:06 EDT
4 Unstoppable Healthcare Stocks to Buy on the DipThe Motley Fool2021-05-26 06:05:00 EDT
Strength Seen in Exact Sciences (EXAS): Can Its 9.2% Jump Turn into Mo...Zacks Investment Research2021-05-21 07:31:05 EDT
Why Exact Sciences Stock Soared TodayThe Motley Fool2021-05-20 15:51:00 EDT
Are You a Glass Half Full or Half Empty Investor?Zacks Investment Research2021-05-19 14:17:03 EDT
Exact Sciences: Emerging Leader In Cancer ScreeningSeeking Alpha2021-05-18 10:00:00 EDT
Exact Sciences (EXAS) Q1 Earnings Top Estimates, Margins DownZacks Investment Research2021-05-05 09:24:32 EDT
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research2021-05-04 18:02:04 EDT
ARK Genomic Revolution ETF: Value Realization Will Take TimeSeeking Alpha2021-05-03 04:46:29 EDT
Why Exact Sciences Stock Sank TodayNasdaq2021-02-17 20:01:00 EDT
Exact Sciences (EXAS) Q4 Earnings, Revenues Top EstimatesBusiness Insider2021-02-17 14:23:00 EDT
Exact Sciences Announces Fourth Quarter 2020 ResultsMarketWatch2021-02-17 12:32:00 EDT
Exact Sciences (EXAS) Q4 2020 Earnings Call TranscriptBusiness Insider2021-02-17 11:30:00 EDT
Exact Sciences EPS misses by $2.59, beats on revenueSeeking Alpha2021-02-16 23:34:00 EDT
Recap: Exact Sciences Q4 EarningsBenzinga.com2021-02-16 21:45:00 EDT
A Preview Of Exact Sciences's EarningsBenzinga.com2021-02-15 15:34:00 EDT
Here's what to expect from EXACT Sciences's earnings reportBusiness Insider2021-02-14 14:01:00 EDT
Click to expand the area.
Income Statements:
EXAS - Exact Sciences Corporation Income Statement
Unit: (milllion)2018Q22018Q32018Q42019Q12019Q22019Q32019Q42020Q12020Q22020Q32020Q42021Q1
Qtr Revenue102.89118.29142.98162.04199.87218.81295.57347.82268.87408.36466.34402.08
Rev Growth yoy78.49 %62.99 %63.58 %79.46 %94.25 %84.97 %106.72 %114.65 %34.52 %86.63 %57.77 %15.60 %
Cost of Revenue26.9030.0038.2043.3051.6052.8069.1081.6066.2095.1099.70110.00
Gross Profit75.9988.29104.78118.74148.27166.00226.47266.22202.67313.26366.64292.08
Gross Profit Mgn73.86 %74.64 %73.28 %73.28 %74.18 %75.87 %76.62 %76.54 %75.38 %76.71 %78.62 %72.64 %
Research and Development14.7117.6320.9332.0230.2034.9542.5343.5132.6731.47446.40115.57
Selling & Marketing Expense29.6034.1040.7051.4046.7043.6057.1045.9041.00136.48186.14
General & Administrative Expense64.4077.4092.40103.50105.20123.20207.00235.80184.60115.60547.40267.70
Interest Expense8.6010.7010.9721.9912.7113.2113.6925.1522.9122.4623.214.62
Operating Expense108.71129.13154.03186.92182.10201.75322.67348.55258.04306.98781.81592.60
Operating Income-32.72-40.84-49.25-68.17-33.83-35.74-96.19-82.33-55.376.28-415.17-300.52
Operating Mgn-31.8 %-34.53 %-34.45 %-42.07 %-16.93 %-16.33 %-32.54 %-23.67 %-20.59 %1.54 %-89.03 %-74.74 %
Net Income-36.39-45.36-53.97-83.06-38.42-40.4677.94-105.70-86.14-219.88-436.81-31.16
Net Income Mgn-35.36 %-38.35 %-37.75 %-51.26 %-19.22 %-18.49 %26.37 %-30.39 %-32.04 %-53.85 %-93.67 %-7.75 %
Generated by @earningsfly with ❤️
Cashflow Statements:
EXAS - Exact Sciences Corporation Cashflow Statement
Unit: (million)2018Q22018Q32018Q42019Q12019Q22019Q32019Q42020Q12020Q22020Q32020Q42021Q1
Operating Cashflows-25.51-4.05-0.85-74.1516.95-29.15-25.30-49.83-6.8781.78111.40-77.23
Financing Cashflows233.2819.079.35240.135.450.986.62979.4816.124.16879.867.25
Investing Cashflows-130.78-78.99-9.80-41.20-102.54857.44-838.13-405.85-6.3816.83-306.64-317.51
Total Capital Expenditures29.1153.6352.5510.8069.0351.6740.3012.6920.7714.3316.5737.92
Changes In Cash76.97-63.96-1.27124.77-39.72-42.1977.94523.81-68.54-200.38-436.81-387.49
Free Cash flow-54.62-57.68-53.78-85.20-51.87-80.75-68.99-62.51-27.6467.4594.83-90.15
Generated by @earningsfly with love ❤️
Balance Sheets:
EXAS - Exact Sciences Corporation Balance Sheet
Unit: (milllion)2018Q22018Q32018Q42019Q12019Q22019Q32019Q42020Q12020Q22020Q32020Q42021Q1
Total Assets1482.651509.581524.021770.551781.941759.273505.774461.134467.734354.374925.096734.52
Intangible Assets23.1122.4946.2845.6145.0544.382346.752365.422342.792109.332084.804257.85
Goodwill1.981.9817.2817.2817.2817.281203.201237.161237.671237.671237.672183.91
Current Assets1310.301289.581228.071407.121374.801319.98553.941484.321504.861606.632198.591775.30
Current Cash225.66161.71160.43285.20205.061034.33177.25701.05703.93806.681491.291103.82
Account Receivables36.2741.9244.2456.0963.9082.20130.67140.05163.61206.61233.19256.13
Inventory35.4138.6239.1544.2747.7853.6761.7269.4282.2280.4392.2789.03
Total Liabilities738.26792.85843.08993.611016.411010.981217.711923.471956.542017.272689.543085.52
Account Payables10.9932.7428.1417.5519.9019.1625.9738.0531.0026.0635.7134.70
Short Term Debt4.590.000.010.020.410.600.8324.571.321.321.321.32
Long Term Debt647.92656.3424.26770.51805.62816.4225.001514.311557.331577.6123.752197.86
Current Ratio15.7912.089.028.392.792.752.346.096.776.353.472.82
Debt Ratio0.440.430.020.440.450.460.010.340.350.360.010.33
Debt/Equity Ratio0.880.920.040.991.051.090.010.810.620.680.01602.68
Generated by @earningsfly with ❤️
Latest Posts:
Not available at this time..
Exact Sciences Corporation
(NASDAQ:EXAS)
Exact Sciences Corporation

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid the...
Sector: Healthcare
Industry: Diagnostics & Research
Full Time Employees: 4,900
Next Earnings Date: 2021-07-28
Keywords: exact sciences
Summary and stock analysis:
  • Return on equity score:
  • Return on assets score:
  • P/E ratio score:
  • P/B ratio score:
  • P/S ratio score:
  • Revenue growth score:
2.5K Followers
5798 Followers
Avg: 
 91 review, 206 jobs
Basic Info:
  • Market Cap: 20.20B
  • Exchange: NASDAQ
  • Shares Float: 169,983,000
  • Shares Outstanding: 171,551,000
  • Revenue Per Employee:
Advanced Info:
  • ROE ttm: -24.10 %
  • ROA ttm: -7.61 %
  • Beta: 1.383
  • EPS: -1.763
  • Debt Ratio ttm: 0.46
  • Debt / Equity Ratio ttm: 0.85
  • Payout Ratio ttm:
Cash Ratios:
  • Cash Ratio ttm: 1.76
  • Current Ratio ttm: 2.82
  • Quick Ratio ttm: 2.6
Key Ratios:
  • P/E trailing 12 month: -26.1
  • P/E forward:
  • P/E trailing 12m high: -15.68
  • P/E trailing 12m low: -35.02
  • P/S trailing 12 month: 13.07
  • EV/S trailing 12 month: 13.69
  • P/B trailing 12 month: 5.53
  • PEG ratio: -1.07
Shorts:
  • Shares Short: 9,326,800
  • Shares Short Prev Month: 9,347,300
  • Days to Cover: 7.02
  • Short Percent Float: 5.49 %
  • Short Percent Outstanding: 5.00 %
Ownership:
  • Percent Insiders: 0.75 %
  • Percent Institutions: 93.62 %
Margins:
  • Gross Profit Margin ttm: 76.00 %
  • EBITDA Margin ttm: -11.00 %
  • Operating Margin ttm: -44.10 %
  • Net Income Margin ttm: -50.00 %
Target Prices:
  • Target Price High: 170 USD
  • Target Price Low: 120 USD
  • Target Price Mean: 154.67 USD
  • Number of Analysts: 18
Key Prices:
  • 52 Week High: 158
  • 52 Week Low: 70.75
  • 50 Day Moving Average: 120.56
  • 200 Day Moving Average: 126.73
Dividends:
  • Trailing Dividend yld:
  • Forward Dividend yld:
  • Payout Ratio:
  • Ex-Dividend date: None
Current Quarter Estimates:
  • Current Quarter EPS estimate: -0.98 ~ -0.51 (2021-06-30)
  • Current Quarter revenue estimate: 407.36M ~ 425.80M
  • Median revenue growth YoY estimate: 54.94%
As of: 2021-07-25
Click to expand the area.
Analyst Consensus:
EXAS - Exact Sciences Corporation Analyst Opinions
Target high: 170 USD
Target low: 120 USD
Average: 154.67 USD based on 18 analysts as of 2021-07-03

Generated by @earningsfly with ❤️
Analyst Trends:
EXAS - Exact Sciences Corporation Analyst Trends
Target high: 170 USD
Target low: 120 USD
Average: 154.67 USD based on 18 analysts as of 2021-07-03
Generated by @earningsfly with ❤️
Website Ranking Analysis:
EXAS - Exact Sciences Corporation  World Website Ranking Analysis
Generated by @earningsfly with ❤️
Google Trends Analysis:
EXAS - Exact Sciences Corporation Google 5-year Trends Analysis
Keyword: Exact Sciences
Generated by @earningsfly with ❤️
Employees Analysis:
EXAS - Exact Sciences Corporation Employees Analysis
Generated by @earningsfly with ❤️
Institution & Insiders Analysis:
EXAS - Exact Sciences Corporation Ownership Analysis
Generated by @earningsfly with ❤️
Debt & Cash Analysis:
EXAS - Exact Sciences Corporation Cash and Debt Analysis(unit: milllion USD)
Generated by @earningsfly with ❤️
Short Analysis:
EXAS - Exact Sciences Corporation Shorts Analysis
Generated by @earningsfly with 🚀
Margins and Revenue:
EXAS - Exact Sciences Corporation Revenue and Margins
Generated by @earningsfly with 🚀
Income Statement Analysis:
EXAS - Exact Sciences Corporation Income Statement
Unit: (milllion)2020Q22020Q32020Q42021Q1
Qtr Revenue268.87408.36466.34402.08
Rev Growth yoy34.52 %86.63 %57.77 %15.60 %
Cost of Revenue66.2095.1099.70110.00
Gross Profit202.67313.26366.64292.08
Gross Profit Mgn75.38 %76.71 %78.62 %72.64 %
Research and Development32.6731.47446.40115.57
Selling & Marketing Expense41.00136.48186.14
General & Administrative Expense184.60115.60547.40267.70
Interest Expense22.9122.4623.214.62
Operating Expense258.04306.98781.81592.60
Operating Income-55.376.28-415.17-300.52
Operating Mgn-20.59 %1.54 %-89.03 %-74.74 %
Net Income-86.14-219.88-436.81-31.16
Net Income Mgn-32.04 %-53.85 %-93.67 %-7.75 %
Generated by @earningsfly with ❤️
Earnings Estimate Analysis:
EXAS - Exact Sciences Corporation EPS Estimates
Current Qtr Estimate (dashed line): -0.74
Generated by @earningsfly with ❤️
Cashflow Analysis:
EXAS - Exact Sciences Corporation Cashflow Statement
Unit: (million)2020Q22020Q32020Q42021Q1
Operating Cashflows-6.8781.78111.40-77.23
Financing Cashflows16.124.16879.867.25
Investing Cashflows-6.3816.83-306.64-317.51
Total Capital Expenditures20.7714.3316.5737.92
Changes In Cash-68.54-200.38-436.81-387.49
Free Cash flow-27.6467.4594.83-90.15
Generated by @earningsfly with love ❤️